Self-Reported Time to Diagnosis and Proportions of Rediagnosis in Female Patients with Chronic Conditions in Australia: A Cross-sectional Survey.
chronic conditions
diagnosis
misdiagnosis
women's health
Journal
Women's health reports (New Rochelle, N.Y.)
ISSN: 2688-4844
Titre abrégé: Womens Health Rep (New Rochelle)
Pays: United States
ID NLM: 101768931
Informations de publication
Date de publication:
2022
2022
Historique:
accepted:
19
07
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
4
10
2022
Statut:
epublish
Résumé
The diagnosis of chronic conditions in women is complicated by the historical androcentricity in medical research. Sex and gender gaps in health research may translate to unequal healthcare for women. This cross-sectional survey study aimed to ascertain the median time to diagnosis, proportions of rediagnosis and time to rediagnosis for Australian women with chronic conditions. An online survey collected anonymous data from voluntary participants. Data were analyzed using Stata14. Cox Proportional Hazards model was used to analyze time to diagnosis and rediagnosis. Logistic regression analysis was used to assess the significance of rediagnosis rates by diagnosis, age at diagnosis, income, employment, state of residence, disability status, and Indigenous status. The median time from first appointment to initial diagnosis was 6 months (range 1 day-50 years) (interquartile range [IQR] 3.74 years). The median time to rediagnosis was 4 years (IQR 9) with a range of 1 day-43 years. Almost half of the women ( Median wait times for a diagnosis for women in Australia, when factoring in high rates of rediagnosis and time to rediagnosis, was 4 years. It is important that clinicians are aware of the high rediagnosis rates in female patients with chronic conditions and understand the potential impact of systemic biases on the diagnostic process for women under their care.
Sections du résumé
Background
UNASSIGNED
The diagnosis of chronic conditions in women is complicated by the historical androcentricity in medical research. Sex and gender gaps in health research may translate to unequal healthcare for women. This cross-sectional survey study aimed to ascertain the median time to diagnosis, proportions of rediagnosis and time to rediagnosis for Australian women with chronic conditions.
Methods
UNASSIGNED
An online survey collected anonymous data from voluntary participants. Data were analyzed using Stata14. Cox Proportional Hazards model was used to analyze time to diagnosis and rediagnosis. Logistic regression analysis was used to assess the significance of rediagnosis rates by diagnosis, age at diagnosis, income, employment, state of residence, disability status, and Indigenous status.
Results
UNASSIGNED
The median time from first appointment to initial diagnosis was 6 months (range 1 day-50 years) (interquartile range [IQR] 3.74 years). The median time to rediagnosis was 4 years (IQR 9) with a range of 1 day-43 years. Almost half of the women (
Conclusion
UNASSIGNED
Median wait times for a diagnosis for women in Australia, when factoring in high rates of rediagnosis and time to rediagnosis, was 4 years. It is important that clinicians are aware of the high rediagnosis rates in female patients with chronic conditions and understand the potential impact of systemic biases on the diagnostic process for women under their care.
Identifiants
pubmed: 36185069
doi: 10.1089/whr.2022.0040
pii: 10.1089/whr.2022.0040
pmc: PMC9518795
doi:
Types de publication
Journal Article
Langues
eng
Pagination
749-758Informations de copyright
© Lea Merone et al., 2022; Published by Mary Ann Liebert, Inc.
Déclaration de conflit d'intérêts
No competing financial interests exist.
Références
Ann Rheum Dis. 2015 Mar;74(3):e12
pubmed: 24534758
Arthritis Rheum. 2009 Feb 15;61(2):274-8
pubmed: 19177534
Lupus. 2018 Apr;27(4):681-687
pubmed: 29310537
Am J Epidemiol. 2002 Jul 15;156(2):165-73
pubmed: 12117708
Soc Sci Med. 1997 Jul;45(2):231-46
pubmed: 9225411
J Womens Health (Larchmt). 2013 Mar;22(3):194-202
pubmed: 23414074
Nat Commun. 2019 Feb 8;10(1):666
pubmed: 30737381
Acad Med. 2016 Jul;91(7):1002-6
pubmed: 26839941
Acad Emerg Med. 2008 May;15(5):414-8
pubmed: 18439195
Semin Immunopathol. 2019 Mar;41(2):265-275
pubmed: 30298433
Tex Heart Inst J. 2013;40(4):379-81
pubmed: 24082363
J Clin Transl Endocrinol. 2014 Jul 08;1(3):77-84
pubmed: 29159087
Soc Sci Med. 2017 May;180:106-113
pubmed: 28343109
BMJ Open. 2013 Jun 24;3(6):
pubmed: 23798742
Womens Health Rep (New Rochelle). 2022 Sep 12;3(1):759-767
pubmed: 36185072
Patient Educ Couns. 2008 Oct;73(1):114-20
pubmed: 18640807
BMC Cancer. 2020 Aug 14;20(1):759
pubmed: 32795358
Gend Med. 2010 Feb;7(1):19-27
pubmed: 20189151
Front Physiol. 2021 May 11;12:678507
pubmed: 34045977
PLoS One. 2016 Jun 09;11(6):e0157235
pubmed: 27281286
J Epidemiol Community Health. 2017 Jun;71(6):550-557
pubmed: 27974445
Med J Aust. 2020 Feb;212(2):57-62.e1
pubmed: 31760662
Reumatol Clin. 2016 Mar-Apr;12(2):72-7
pubmed: 26190206
Health Care Women Int. 2022 Jan-Mar;43(1-3):1-4
pubmed: 35138224
Eur Heart J. 2011 Jun;32(11):1313-5
pubmed: 21393339
Womens Health Rep (New Rochelle). 2022 Jan 31;3(1):49-59
pubmed: 35136877
Am J Obstet Gynecol. 2019 Apr;220(4):354.e1-354.e12
pubmed: 30625295
J Womens Health (Larchmt). 2017 Jul;26(7):788-797
pubmed: 28440744
J Womens Health (Larchmt). 2018 Aug;27(8):1035-1044
pubmed: 29608126
BMC Health Serv Res. 2010 Apr 26;10:102
pubmed: 20420681
J Intern Med. 2019 Oct;286(4):438-448
pubmed: 30861229
Dialogues Clin Neurosci. 2016 Dec;18(4):373-383
pubmed: 28179809
Cureus. 2020 Oct 10;12(10):e10881
pubmed: 33178533
Aust N Z J Public Health. 2021 Oct;45(5):424-426
pubmed: 34181298
Int J Environ Res Public Health. 2019 Apr 08;16(7):
pubmed: 30965593
Arch Intern Med. 1997 Mar 10;157(5):537-43
pubmed: 9066458
Isr Med Assoc J. 2003 Jul;5(7):489-90
pubmed: 12901244
Hum Reprod. 1996 Apr;11(4):878-80
pubmed: 8671344
Health Care Women Int. 2009 May;30(5):390-407
pubmed: 19350436
JAMA Netw Open. 2019 Jul 3;2(7):e196700
pubmed: 31268541
PLoS One. 2015 May 15;10(5):e0127717
pubmed: 25978414
Hastings Cent Rep. 1992 Jan-Feb;22(1):24-9
pubmed: 1544796
Br J Gen Pract. 2014 Oct;64(627):e602-10
pubmed: 25267045
Disabil Rehabil. 2019 Dec;41(25):3092-3102
pubmed: 29929450
JAMA. 1994 Oct 26;272(16):1267-70
pubmed: 7933371
Front Immunol. 2019 May 09;10:1076
pubmed: 31156632
Med Educ. 2008 Oct;42(10):1021-8
pubmed: 18761614